دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Clinical Activity of Olvimulogene Nanivacirepvec–Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer
Robert W. Holloway, MD1; Alberto A. Mendivil, MD2,3; James E. Kendrick, MD1; Lisa N. Abaid, MD2,3; John V. Brown, MD2,3; Jane LeBlanc, BS1; Nathalie D. McKenzie, MD1; Kristina M. Mori, MD2,4; Sarfraz Ahmad, PhD1
Association of Food Deserts and Food Swamps With Obesity-Related Cancer Mortality in the US
Malcolm Seth Bevel, PhD, MSPH1; Meng-Han Tsai, PhD1,2; April Parham, BS, TTS1; Sydney Elizabeth Andrzejak, MS1; Samantha Jones, PhD1,2; Justin Xavier Moore, PhD, MPH1,3
Association of MGMT Promoter Methylation With Survival in Low-grade and Anaplastic Gliomas After Alkylating Chemotherapy
Connor J. Kinslow, MD1,2; Ann Mercurio, MS, RN1; Prashanth Kumar, BA1; Ali I. Rae, MD, MPH3; Markus D. Siegelin, MD, PhD2,4,5; Jack Grinband, PhD6,7; Kekoa Taparra, MD, PhD8; Pavan S. Upadhyayula, MD2,9; Guy M. McKhann, MD2,9; Michael B. Sisti, MD2,9; Jeffrey N. Bruce, MD2,9; Peter D. Canoll, MD, PhD2,4,5; Fabio M. Iwamoto, MD2,9; Lisa A. Kachnic, MD1,2; James B. Yu, MD, MHS1,2; Simon K. Cheng, MD, PhD1,2; Tony J. C. Wang, MD1,2
Association of Second-generation Antiandrogens With Cognitive and Functional Toxic Effects in Randomized Clinical Trials
Malgorzata K. Nowakowska, BS1; Rachel M. Ortega, MSA1; Mackenzie R. Wehner, MD, MPhil2,3; Kevin T. Nead, MD, MPhil4,5
Bacterial Decolonization for Prevention of Radiation Dermatitis
Yana Kost, BA1; Alana Deutsch, MD1; Karolina Mieczkowska, MD1; Roya Nazarian, MD1; Ahava Muskat, BA1; H. Dean Hosgood, PhD2,3; Juan Lin, PhD2,3; Johanna P. Daily, MS, MD4,5; Nitin Ohri, MD, MS6; Rafi Kabarriti, MD6; Kosaku Shinoda, PhD7,8; Beth N. McLellan, MD1
Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor–Positive/ERBB2-Positive Early Breast Cancer
Oleg Gluz, MD1,2,3; Ulrike A. Nitz, MD1,2; Matthias Christgen, MD, PhD4; Sherko Kuemmel, MD, PhD1,5,6; Johannes Holtschmidt, MD5,7; Johannes Schumacher, PhD8; Andreas Hartkopf, MD9; Jochem Potenberg, MD10; Kerstin Lüedtke-Heckenkamp, MD11; Marianne Just, MD12; Christian Schem, MD, PhD13; Raquel von Schumann, MD2; Cornelia Kolberg-Liedtke, MD, PhD6,14; Christine Zu Eulenburg, PhD1,15; Timo Schinköthe, MD, PhD16,17; Monika Graeser, MD1,2,18; Rachel Wuerstlein, MD1,16; Ronald E. Kates, PhD1; Hans Heinrich Kreipe, MD, PhD4; Nadia Harbeck, MD, PhD1,16
Risk of Syndrome-Associated Cancers Among First-Degree Relatives of Patients With Pancreatic Ductal Adenocarcinoma With Pathogenic or Likely Pathogenic Germline Variants
Xuan Chen, BS1; Margaret A. Meyer, MS2; Jennifer L. Kemppainen, MS, CGC3; Masayasu Horibe, MD, PhD4; Shruti Chandra, MBBS5; Shounak Majumder, MD6; Gloria M. Petersen, PhD5; Kari G. Rabe, MS7
Association of Staphylococcus aureus Colonization With Severity of Acute Radiation Dermatitis in Patients With Breast or Head and Neck Cancer
Yana Kost, BA1; Alexandra K. Rzepecki, MD1; Alana Deutsch, MD1; Mathew R. Birnbaum, MD1; Nitin Ohri, MD, MS2; H. Dean Hosgood, PhD3; Juan Lin, PhD3; Johanna P. Daily, MD, MS4; Kosaku Shinoda, PhD5,6; Beth N. McLellan, MD1
Panitumumab Plus Trifluridine-Tipiracil as Anti–Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer
Stefania Napolitano, MD, PhD1; Vincenzo De Falco, MD1; Giulia Martini, MD, PhD1; Davide Ciardiello, MD1,2; Erika Martinelli, MD, PhD1; Carminia Maria Della Corte, MD, PhD1; Lucia Esposito, BSc1; Vincenzo Famiglietti, BSc1; Alessandra Di Liello, BSc1; Antonio Avallone, MD3; Claudia Cardone, MD3; Alfonso De Stefano, MD, PhD3; Vincenzo Montesarchio, MD4; Maria Giulia Zampino, MD5; Roberto Bordonaro, MD6; Mario Scartozzi, MD7; Daniele Santini, MD, PhD8; Massimo Di Maio, MD, PhD9; Ferdinando De Vita, MD, PhD1; Lucia Altucci, MD, PhD1; Francesca Marrone, BSc1; Fortunato Ciardiello, MD, PhD1; Teresa Troiani, MD, PhD1
Trends in the Prevalence of Functional Limitations Among US Cancer Survivors, 1999-2018
Vishal R. Patel, BS1; S. M. Qasim Hussaini, MD, MS2; Anne H. Blaes, MD, MS3; Alicia K. Morgans, MD, MPH4; Alex B. Haynes, MD, MPH1; Adewole S. Adamson, MD, MPP1; Arjun Gupta, MD3
American Radium Society Appropriate Use Criteria for Radiation Therapy in the Multidisciplinary Management of Thymic Carcinoma
Stephen G. Chun, MD1; Andreas Rimner, MD2; Arya Amini, MD3; Joe Y. Chang, MD, PhD1; Jessica Donington, MD4; Martin J. Edelman, MD5; Yimin Geng, PhD1; Matthew A. Gubens, MD6; Kristin A. Higgins, MD7; Puneeth Iyengar, MD, PhD8; Benjamin Movsas, MD9; Matthew S. Ning, MD1; Henry S. Park, MD, MPH10; George Rodrigues, MD, PhD11; Andrea Wolf, MD12; Charles B. Simone II, MD13
Implementing Smoking Cessation Interventions for Tobacco Users Within Oncology Settings
Alison L. Young, PhD, MCP1; Elena Stefanovska, BPscyh (Hons)1; Christine Paul, PhD, BA (Hons)1; Kristen McCarter, PhD, BPsych (Hons)1; Melissa McEnallay, MPH, BHealth1; Jordan Tait, BPsych (Hons)1; Shalini Vinod, MBBS, MD2,3; Kate White, RN, PhD, MN, CertOnc, CertPall4; Fiona Day, MBBS, BSc (Hons), PhD1,5; Emily Stone, MBBS, MMed6,7
Missing, Inconsistent, and Other—A Call to Improve Transgender Representation in Oncology Research
Luca Borah, BA1; Megan Lane, MD, MS2; Hari Nathan, MD, PhD3
Vaccinia (Smallpox) for the Treatment of Ovarian Cancer—Turning an Old Foe Into a Friend?
Erica S. Tsang, MD, MPH1,2; Pamela N. Munster, MD1
A Critical Need to Examine the Lack of Access to Healthy Quality Foods and Its Association With Cancer Mortality—A Clarion Call for Multilevel Research and Interventions
Karriem S. Watson, DHSc, MS, MPH1; Angela Odoms-Young, PhD2
MGMTÂ Methylation Status in Grades 2 and 3 Gliomas Is Important, but Is It Prognostic?
Kelli B. Pointer, MD, PhD1; Na Tosha N. Gatson, MD, PhD2
Balancing Treatment Benefits of Androgen-Receptor Signal Inhibitors and Quality of Life in Patients With Prostate Cancer
Alexandra O. Sokolova, MD1; Julie N. Graff, MD1,2
Reporting of Immunotherapy and Biologic Therapy in the National Cancer Database
J. Bryan Iorgulescu, MD, MPH1
Reporting of Immunotherapy and Biologic Therapy in the National Cancer Database—Reply
Sameh Hany Emile, MBBCh, MSc, MD1,2; Nir Horesh, MD1,3; Steven D. Wexner, MD1
Evidence on Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma
Zhen Gao, MD1,2; Sichao Wang, MD1,3,4; Shujie Huang, MD1
Evidence on Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma—Reply
Joseph J. Zhao, MBBS1,2; Filippo Pietrantonio, MD3; Raghav Sundar, MBBS, PhD1,2
External Control Arms and Data Analysis Methods in Nonrandomized Trial of Patients With Glioblastoma
Jacob J. Mandel, MD1; John F. de Groot, MD2
External Control Arms and Data Analysis Methods in Nonrandomized Trial of Patients With Glioblastoma
Rifaquat Rahman, MD1; Steffen Ventz, PhD2; Lorenzo Trippa, PhD3
External Control Arms and Data Analysis Methods in Nonrandomized Trial of Patients With Glioblastoma—Reply
Linda M. Liau, MD, PhD1; Keyoumars Ashkan, MD2; Marnix L. Bosch, PhD3
Tucatinib Plus Trastuzumab and Capecitabine for ERBB2 (HER2)-Positive Metastatic Breast Cancer With Brain Metastases
Dun-Chang Mo, MD1; Peng-Hui Luo, MD1; Jian-Feng Huang, MD1
Tucatinib Plus Trastuzumab and Capecitabine for ERBB2 (HER2)-Positive Metastatic Breast Cancer With Brain Metastases—Reply
Nancy U. Lin, MD1
